These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 29316712)
41. Silibinins and curcumin as promising ligands against mutant cystic fibrosis transmembrane regulator protein. Akram A; Sakhawat A; Ghani MU; Khan MU; Rehman R; Ali Q; Jin-Liang P; Ali D AMB Express; 2024 Jul; 14(1):84. PubMed ID: 39043981 [TBL] [Abstract][Full Text] [Related]
42. Psoralen derivatives as inhibitors of NF-κB/DNA interaction: synthesis, molecular modeling, 3D-QSAR, and biological evaluation. Marzaro G; Guiotto A; Borgatti M; Finotti A; Gambari R; Breveglieri G; Chilin A J Med Chem; 2013 Mar; 56(5):1830-42. PubMed ID: 23414143 [TBL] [Abstract][Full Text] [Related]
43. Molecular modeling in the age of clinical genomics, the enterprise of the next generation. Prokop JW; Lazar J; Crapitto G; Smith DC; Worthey EA; Jacob HJ J Mol Model; 2017 Mar; 23(3):75. PubMed ID: 28204942 [TBL] [Abstract][Full Text] [Related]
44. Insights on peptide topology in the computational design of protein ligands: the example of lysozyme binding peptides. Cantarutti C; Vargas MC; Dongmo Foumthuim CJ; Dumoulin M; La Manna S; Marasco D; Santambrogio C; Grandori R; Scoles G; Soler MA; Corazza A; Fortuna S Phys Chem Chem Phys; 2021 Oct; 23(40):23158-23172. PubMed ID: 34617942 [TBL] [Abstract][Full Text] [Related]
45. The solid-phase Zincke reaction: preparation of omega-hydroxy pyridinium salts in the search for CFTR activation. Eda M; Kurth MJ; Nantz MH J Org Chem; 2000 Aug; 65(17):5131-5. PubMed ID: 10993337 [TBL] [Abstract][Full Text] [Related]
46. Profile of an unknown airway cell. Travaglini KJ; Krasnow MA Nature; 2018 Aug; 560(7718):313-314. PubMed ID: 30097657 [No Abstract] [Full Text] [Related]
47. Preclinical Modeling for Therapeutic Development in Cystic Fibrosis. Bonfield TL Am J Respir Crit Care Med; 2020 Feb; 201(3):267-268. PubMed ID: 31697560 [No Abstract] [Full Text] [Related]
48. Three modulator drugs are better than two in cystic fibrosis. Arch Dis Child; 2019 Jan; 104(1):75. PubMed ID: 30504440 [No Abstract] [Full Text] [Related]
49. Cystic fibrosis drugs are rejected for NHS use in Scotland. Christie B BMJ; 2019 Aug; 366():l5137. PubMed ID: 31409602 [No Abstract] [Full Text] [Related]
51. Partial rescue of F508del-cystic fibrosis transmembrane conductance regulator channel gating with modest improvement of protein processing, but not stability, by a dual-acting small molecule. Liu J; Bihler H; Farinha CM; Awatade NT; Romão AM; Mercadante D; Cheng Y; Musisi I; Jantarajit W; Wang Y; Cai Z; Amaral MD; Mense M; Sheppard DN Br J Pharmacol; 2018 Apr; 175(7):1017-1038. PubMed ID: 29318594 [TBL] [Abstract][Full Text] [Related]
52. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis. Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948 [TBL] [Abstract][Full Text] [Related]
53. Development of an airway mucus defect in the cystic fibrosis rat. Birket SE; Davis JM; Fernandez CM; Tuggle KL; Oden AM; Chu KK; Tearney GJ; Fanucchi MV; Sorscher EJ; Rowe SM JCI Insight; 2018 Jan; 3(1):. PubMed ID: 29321377 [TBL] [Abstract][Full Text] [Related]
54. Infection Is Not Required for Mucoinflammatory Lung Disease in CFTR-Knockout Ferrets. Rosen BH; Evans TIA; Moll SR; Gray JS; Liang B; Sun X; Zhang Y; Jensen-Cody CW; Swatek AM; Zhou W; He N; Rotti PG; Tyler SR; Keiser NW; Anderson PJ; Brooks L; Li Y; Pope RM; Rajput M; Hoffman EA; Wang K; Harris JK; Parekh KR; Gibson-Corley KN; Engelhardt JF Am J Respir Crit Care Med; 2018 May; 197(10):1308-1318. PubMed ID: 29327941 [TBL] [Abstract][Full Text] [Related]
55. Compartmentalized crosstalk of CFTR and TMEM16A (ANO1) through EPAC1 and ADCY1. Lérias J; Pinto M; Benedetto R; Schreiber R; Amaral M; Aureli M; Kunzelmann K Cell Signal; 2018 Apr; 44():10-19. PubMed ID: 29331508 [TBL] [Abstract][Full Text] [Related]
56. Thymosin α-1 does not correct F508del-CFTR in cystic fibrosis airway epithelia. Tomati V; Caci E; Ferrera L; Pesce E; Sondo E; Cholon DM; Quinney NL; Boyles SE; Armirotti A; Ravazzolo R; Galietta LJ; Gentzsch M; Pedemonte N JCI Insight; 2018 Feb; 3(3):. PubMed ID: 29415893 [TBL] [Abstract][Full Text] [Related]
57. The CFTR-Associated Ligand Arrests the Trafficking of the Mutant ΔF508 CFTR Channel in the ER Contributing to Cystic Fibrosis. Bergbower E; Boinot C; Sabirzhanova I; Guggino W; Cebotaru L Cell Physiol Biochem; 2018; 45(2):639-655. PubMed ID: 29402832 [TBL] [Abstract][Full Text] [Related]
58. Conformational change of the extracellular parts of the CFTR protein during channel gating. Negoda A; Cowley EA; El Hiani Y; Linsdell P Cell Mol Life Sci; 2018 Aug; 75(16):3027-3038. PubMed ID: 29441426 [TBL] [Abstract][Full Text] [Related]
59. Virtual Drug Repositioning as a Tool to Identify Natural Small Molecules That Synergize with Lumacaftor in F508del-CFTR Binding and Rescuing. Fossa P; Uggeri M; Orro A; Urbinati C; Rondina A; Milanesi M; Pedemonte N; Pesce E; Padoan R; Ford RC; Meng X; Rusnati M; D'Ursi P Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293130 [TBL] [Abstract][Full Text] [Related]
60. Molecular mechanisms of cystic fibrosis - how mutations lead to misfunction and guide therapy. Farinha CM; Callebaut I Biosci Rep; 2022 Jul; 42(7):. PubMed ID: 35707985 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]